My bookmarksSign up free

Commission Implementing Regulation (EU) 2026/1826 of 28 July 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances aclonifen, amisulbrom, Bacillus amyloliquefaciens strain MBI 600, beflubutamid, clomazone, cyantraniliprole, cyprodinil, daminozide, dichlorprop-P, dimethachlor, fludioxonil, formetanate, fosetyl, isofetamid, metalaxyl, metazachlor, penconazole, phenmedipham, pirimicarb, pyraclostrobin and S-abscisic acid

Commission Implementing Regulation (EU) 2026/1826 of 28 July 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances aclonifen, amisulbrom, Bacillus amyloliquefaciens strain MBI 600, beflubutamid, clomazone, cyantraniliprole, cyprodinil, daminozide, dichlorprop-P, dimethachlor, fludioxonil, formetanate, fosetyl, isofetamid, metalaxyl, metazachlor, penconazole, phenmedipham, pirimicarb, pyraclostrobin and S-abscisic acid

Implementing Regulation (EU) 2026/1826 · Regulation · 3 articles

Data as of 2026-08-06 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

ANNEX The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows: (1) Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 81, Pyraclostrobin, the date is replaced by ‘15 December 2026’; (2) in the sixth column, expiration of approval, of row 88, Phenmedipham, the date is replaced by ‘30 September 2027’; (3) in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘15 December 2027’; (4) in the sixth column, expiration of approval, of row 124, Pirimicarb, the date is replaced by ‘31 July 2027’; (5) in the sixth column, expiration of approval, of row 130, Cyprodinil, the date is replaced by ‘31 July 2027’; (6) in the sixth column, expiration of approval, of row 131, Fosetyl, the date is replaced by ‘31 January 2028’; (7) in the sixth column, expiration of approval, of row 133, Dichlorprop-P, the date is replaced by ‘31 October 2027’; (8) in the sixth column, expiration of approval, of row 147, Formetanate, the date is replaced by ‘30 September 2027’; (9) in the sixth column, expiration of approval, of row 158, Beflubutamid, the date is replaced by ‘31 July 2028’; (10) in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘30 September 2027’; (11) in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘31 December 2027’; (12) in the sixth column, expiration of approval, of row 215, Aclonifen, the date is replaced by ‘31 March 2029’; (13) in the sixth column, expiration of approval, of row 217, Metazachlor, the date is replaced by ‘31 May 2029’; (14) in the sixth column, expiration of approval, of row 284, Dimethachlor, the date is replaced by ‘31 March 2029’; (15) in the sixth column, expiration of approval, of row 287, Penconazole, the date is replaced by ‘15 February 2029’; (16) in the sixth column, expiration of approval, of row 304, Metalaxyl, the date is replaced by ‘30 June 2029’; (2) Part B is amended as follows: (1) in the sixth column, expiration of approval, of row 65, S-abscisic acid, the date is replaced by ‘15 April 2029’; (2) in the sixth column, expiration of approval, of row 69, Amisulbrom, the date is replaced by ‘15 March 2030’; (3) in the sixth column, expiration of approval, of row 99, Cyantraniliprole, the date is replaced by ‘14 March 2030’; (4) in the sixth column, expiration of approval, of row 100, Isofetamid, the date is replaced by ‘15 March 2030’; (5) in the sixth column, expiration of approval, of row 101, Bacillus amyloliquefaciens strain MBI 600, the date is replaced by ‘1 December 2029’.

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next